Cargando…
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Nitrosoureas are the drugs most effective in the treatment of patients with intracerebral malignant glioma. Their limiting toxicity is delayed myelosuppression. A prospective, randomised crossover study of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was performed in...
Autores principales: | Rampling, R., Steward, W., Paul, J., Macham, M. A., Harvey, E., Eckley, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968853/ https://www.ncbi.nlm.nih.gov/pubmed/8123485 |
Ejemplares similares
-
Tumor growth under rhGM-CSF application in an orthotopic rodent glioma model
por: Linsenmann, Thomas, et al.
Publicado: (2019) -
Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim)
por: Gajewska, Marta E., et al.
Publicado: (2018) -
Topically administered rhGM-CSF affects PPARβ expression in the stasis zone
por: Fu, Gen-Feng, et al.
Publicado: (2017) -
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.
por: Steward, W. P., et al.
Publicado: (1989) -
Bioavailability of Orally Administered rhGM-CSF: A Single-Dose, Randomized, Open-Label, Two-Period Crossover Trial
por: Zhang, Wenping, et al.
Publicado: (2009)